The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial
- PMID:24002152
The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial
Abstract
Topical treatments, such as adapalene and benzoyl peroxide (BPO), are popular in mild-to-moderate acne vulgaris. This study aimed to compare the efficacy, safety and tolerability of adapalene and BPO in mild acne vulgaris. In this single-center, randomized, double-blind, clinical trial, 60 patients with mild acne vulgaris received either topical adapalene 0.1% gel or topical BPO 2.5% gel on their face once daily for two months. The changes of acne lesion count (efficacy), any adverse effect (safety), and the patients' overall satisfaction (tolerability) were compared after 3 months of follow-up. In both groups the mean number of noninflammatory, inflammatory and total lesions decreased significantly from baseline (10.77±5.54, 9.73±5.09, and 20.50±7.54, respectively in adapalene group; 11.50±5.92, 8.43±5.45, and 19.93±9.01, respectively in BPO group) to the third month (1.70±1.68, 0.33±0.66, and 0.50±0.78, respectively in adapalene group; 4.23±4.14, 0.33±0.71, and 4.13±4.44, respectively in BPO group; P<0.001 for all), posttreatment. Although the mean number of inflammatory lesions was significantly lower in BPO receivers only at first month (P=0.001), the mean number of noninflammatory and total lesions was significantly lower in adapalene group at second (P= 0.04 and 0.03, respectively) and third (P=0.02 and <0.001, respectively) months, posttreatment. The adverse events were minimal and self-limited (26.7% in adapalene group, 20% in BPO group, P=0.54). The patients' overall satisfaction was good-excellent in 93.3% of adapalene receivers vs. 73.3% in BPO group (P=0.08). Both topical adapalene 0.1% and BPO 2.5% gels seem safe and effective in mild acne vulgaris, with a marginal tendency toward the former.
Similar articles
- The efficacy, safety, and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris: a randomized trial.Babaeinejad SH, Fouladi RF.Babaeinejad SH, et al.J Drugs Dermatol. 2013 Jul 1;12(7):790-4.J Drugs Dermatol. 2013.PMID:23884492Clinical Trial.
- Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides.Eichenfield LF, Draelos Z, Lucky AW, Hebert AA, Sugarman J, Stein Gold L, Rudisill D, Liu H, Manna V.Eichenfield LF, et al.J Drugs Dermatol. 2013 Jun 1;12(6):611-8.J Drugs Dermatol. 2013.PMID:23839175Clinical Trial.
- Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients.Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu Y, Graeber M; Adapalene-BPO Study Group.Gollnick HP, et al.Br J Dermatol. 2009 Nov;161(5):1180-9. doi: 10.1111/j.1365-2133.2009.09209.x. Epub 2009 May 21.Br J Dermatol. 2009.PMID:19466959Clinical Trial.
- Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years.Keating GM.Keating GM.Am J Clin Dermatol. 2011 Dec 1;12(6):407-20. doi: 10.2165/11208170-000000000-00000.Am J Clin Dermatol. 2011.PMID:21967116Review.
- Adapalene 0.1% and benzoyl peroxide 2.5%: a novel combination for treatment of acne vulgaris.Tan JK.Tan JK.Skin Therapy Lett. 2009 Jul-Aug;14(6):4-5.Skin Therapy Lett. 2009.PMID:19609474Review.
Cited by
- A dermocosmetic containing bakuchiol, Ginkgo biloba extract and mannitol improves the efficacy of adapalene in patients with acne vulgaris: result from a controlled randomized trial.Poláková K, Fauger A, Sayag M, Jourdan E.Poláková K, et al.Clin Cosmet Investig Dermatol. 2015 Apr 10;8:187-91. doi: 10.2147/CCID.S81691. eCollection 2015.Clin Cosmet Investig Dermatol. 2015.PMID:25914553Free PMC article.
- Topical benzoyl peroxide for acne.Yang Z, Zhang Y, Lazic Mosler E, Hu J, Li H, Zhang Y, Liu J, Zhang Q.Yang Z, et al.Cochrane Database Syst Rev. 2020 Mar 16;3(3):CD011154. doi: 10.1002/14651858.CD011154.pub2.Cochrane Database Syst Rev. 2020.PMID:32175593Free PMC article.
- Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed-dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: A multicenter, randomized, investigator-blind, parallel-group study.Hayashi N, Kurokawa I, Siakpere O, Endo A, Hatanaka T, Yamada M, Kawashima M.Hayashi N, et al.J Dermatol. 2018 Aug;45(8):951-962. doi: 10.1111/1346-8138.14497. Epub 2018 Jun 15.J Dermatol. 2018.PMID:29905384Free PMC article.Clinical Trial.
- Optimization and validation of high-performance chromatographic condition for simultaneous determination of adapalene and benzoyl peroxide by response surface methodology.Chen YC, Tsai PJ, Huang YB, Wu PC.Chen YC, et al.PLoS One. 2015 Mar 20;10(3):e0120171. doi: 10.1371/journal.pone.0120171. eCollection 2015.PLoS One. 2015.PMID:25793581Free PMC article.
- Synchronizing Pharmacotherapy in Acne with Review of Clinical Care.Sacchidanand SA, Lahiri K, Godse K, Patwardhan NG, Ganjoo A, Kharkar R, Narayanan V, Borade D, D'souza L.Sacchidanand SA, et al.Indian J Dermatol. 2017 Jul-Aug;62(4):341-357. doi: 10.4103/ijd.IJD_41_17.Indian J Dermatol. 2017.PMID:28794543Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical